We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 04, 2022

Upregulation of POM121 Is Linked to Prostate Cancer Aggressiveness and Serves as a Prognostic Biomarker

Urologic Oncology: Seminars and Original Investigations


Additional Info

Urologic Oncology: Seminars and Original Investigations
Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker
Urol. Oncol 2022 Jun 17;[EPub Ahead of Print], F Becker, A Offermann, MC Roesch, V Joerg, D Roth, V Lubczyk, R Kuefer, V Sailer, J Kirfel, AS Merseburger, S Perner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading